Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhijuan LinLLLong LiuYHYan Hong

Discussion

Loading...

Member takes

Overview

Phase II study shows high complete remission rates in high-tumor-burden follicular lymphoma, indicating manageable toxicity and efficacy of the treatment.

Key Points

  • High complete remission rates were achieved in patients with high-tumor-burden follicular lymphoma after treatment.
  • Fifteen percent reported Grade 1-2 infusion-related reactions, reflecting manageable safety profile.
  • Phase II study employed Zanubrutinib and Obinutuzumab as a chemo-free regimen for first-line treatment.
  • This treatment suggests potential benefits while minimizing the toxicity associated with conventional chemotherapy.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d459https://doi.org/10.1182/blood-2025-1818
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  2. 2Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma2025
  3. 3Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025
  4. 4Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  5. 5A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis2025